Zynex experienced a sharp downturn in revenue and earnings during Q3 2025 due to reimbursement issues, workforce reductions, and a large impairment charge. The company reported a net loss of $42.9 million and negative operating cash flow.

Zynex reported Q4 2024 revenue of $46.0 million, a slight decline from the prior year. The company posted a net loss of $0.6 million, or ($0.02) per share. Adjusted EBITDA was significantly lower year-over-year at $0.6 million. Cash flow from operations for the quarter was $2.4 million. The company faces revenue challenges due to payment suspensions but is restructuring to manage costs and expects improvements in 2025.

Zynex reported a 13% year-over-year increase in orders for Q3 2024. The company's revenue and earnings were within the provided guidance. They also received FDA clearance for their new TensWave device.

Zynex reported an 11% increase in revenue for Q2 2024, reaching $49.9 million, driven by a 20% growth in device orders. However, revenue was below previous guidance due to a reduction in sales representatives and a changing product mix. Net income was $1.2 million, with diluted EPS of $0.04.

Zynex reported a 10% increase in revenue for Q1 2024, reaching $46.5 million, although it underperformed guidance due to delayed insurer payments. Net income was $10,000, with diluted EPS at $0.00. The company reaffirmed its 2024 revenue guidance of at least $227 million, driven by order growth and new product introductions.

Zynex reported a decrease in revenue for Q4 2023 to $47.3 million, a 3% decrease year-over-year, due to a $6.2 million non-recurring write-off. FY 2023 revenue increased 17% year-over-year to $184.3 million. The company's net income for Q4 2023 was $1.2 million, with diluted EPS of $0.04. The Board of Directors has approved an additional $20.0 million of the Company’s common stock.

Zynex reported a 20% increase in revenue to $49.9 million and EPS of $0.10 for Q3 2023. The company achieved record-high order numbers and positive cash flow, driven by its pain management division. They also introduced three new therapy products and are developing the next generation of patient monitoring equipment.

Zynex reported a 22% increase in revenue to $45.0 million for Q2 2023, with EPS at $0.09. The company saw a 51% growth in device orders and continued its stock buyback program.

Zynex announced strong Q1 2023 results, marked by a 36% increase in net revenue year-over-year, reaching $42.2 million. The company also reported a 14% increase in net income, amounting to $1.6 million. The company's cash from operations increased by 10% compared to the same period in 2022.

Zynex, Inc. reported strong Q4 2022 financial results with a 21% increase in net revenue and a 53% increase in net income from the previous quarter. The company's cash flow from operations allowed for significant stock buybacks, and Zynex Monitoring Solutions is making progress with clinical data collection.

Zynex reported a 19% increase in net revenue to $41.5 million compared to Q3 2021. Net income increased by 46% from the previous quarter to $4.9 million. The company had $23.5 million in cash on hand and generated $7.4 million in operating cash flow.

Zynex reported net revenue of $36.8 million for the second quarter of 2022, an 18% increase over the second quarter of 2021. Net income was $3.3 million, a 19% increase from Q2 2021.

Zynex reported a strong first quarter with a 29% increase in net revenue and a 296% increase in net income compared to Q1 2021. The company's cash collections were strong, and they initiated a stock buyback program.

Zynex reported a strong fourth quarter with record revenue of $40.4 million, a 58% increase year-over-year, and net income of $8.9 million, a 398% increase year-over-year.

Zynex reported record revenue of $34.8 million and net income of $6.1 million for the third quarter of 2021. The company's order growth increased by 70%, driving increasing revenue. They also submitted their next generation CM-1600 for FDA clearance within the next ninety days.

Zynex reported a strong second quarter with record revenue of $31.0 million, a 61% increase year-over-year, and a net income of $2.8 million. The company's order growth was significant at 247%.

Zynex reported a strong revenue increase of 58% year-over-year for Q1 2021, reaching $24.1 million. However, the company experienced a net loss of $0.7 million due to seasonal factors and investments in the sales force. The company anticipates profitability to improve significantly in the second quarter.

Zynex reported an 81% increase in net revenue to $25.6 million and a net income of $1.8 million for the fourth quarter of 2020. Orders grew 117% compared to Q4 2019.

Zynex reported strong third-quarter results, highlighted by a 69% increase in revenue to $20.0 million and a net income of $1.3 million. The company's growth strategy and sales force expansion contributed to the positive performance, with orders growing 96% compared to the third quarter of 2019.

Zynex reported an 87% increase in net revenue to $19.3 million and a net income of $3.0 million for the second quarter of 2020. The company's order growth was 37% compared to the second quarter of 2019.

Zynex reported a strong first quarter with a 66% increase in revenue to $15.2 million and a net income of $2.9 million, marking the fifteenth consecutive quarter of positive net income. The company also saw significant order growth and generated $0.6 million in cash from operations.

Zynex reported strong fourth-quarter results with a 52% increase in net revenue, reaching $14.2 million, and a net income of $2.9 million. Order growth was significant, increasing by 129% compared to the fourth quarter of 2018. The company is focused on expanding its sales force and investing in infrastructure to support increasing order volumes.